361 HCT/P Compliant Tissue Products in Milwaukee, WI

What I’d check before adding 361 hctp compliant products here

Joe Bradley will tell you the same thing he tells his own staff: epidemiology first, then MAC, then SKU. CDC PLACES (2023, crude) estimates 14.7% of adults in Milwaukee have diagnosed diabetes — 2.7 points above the U.S. 12% figure. 14.1% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. Then we pick 361 hctp compliant products against that mix.

Where Milwaukee programs actually stall

• CDC PLACES (2023, crude) estimates 14.7% of adults in Milwaukee have diagnosed diabetes — 2.7 points above the U.S. 12% figure. Adult arthritis here is 23.8% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. Separate 361 tissue, PRP, and CTP tickets before you market 361 hctp compliant products in Milwaukee. Mixing lanes is how recoupments start.
• Joint-preservation biologics compete with cortisone and viscosupplementation pathways that already have familiar CPT habits. The operational gap in Wisconsin is staff training and consent language, not another brand name on a centrifuge.
• Wisconsin Department of Health Services publishes state chronic-disease context that clinics can cite in patient education. Pair that with FDA 361 labeling — homologous use, minimal manipulation — so marketing does not outrun the product's actual regulatory lane.

Uninsured mix and Medicare CTPs in the same building

J6 reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Milwaukee is 14.7% or not. PLACES is planning data. The LCD is the claim.

How we’d stand this up in clinic